Kurs
+13,31%
Kurs
+13,31%
Open
0,60
High
0,89
Low
0,60
Close
0,63
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
6,84 MNOK
Likviditet
6,84 MNOK
Rel. mcap
9,92%
Antal aktier
9 292 903
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2025-08-28 | 18:50 | Kvartalsrapport 2025-Q2 |
| 2025-06-06 | N/A | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2025-06-05 | N/A | Årsstämma |
| 2025-04-10 | - | Bokslutskommuniké 2024 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-19 | - | Årsstämma |
| 2024-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2024-04-25 | - | Bokslutskommuniké 2023 |
| 2023-10-04 | - | Split CRNA 30:1 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2023-03-09 | - | Extra Bolagsstämma 2023 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-20 | - | Årsstämma |
| 2022-04-07 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Extra Bolagsstämma 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-18 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2021-03-17 | - | Årsstämma |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-30 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2020-04-29 | - | Årsstämma |
| 2020-03-11 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-10 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2019-04-09 | - | Årsstämma |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-01 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-12 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2018-04-11 | - | Årsstämma |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-05 | - | Årsstämma |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-14 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2016-04-13 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-04-11 07:00:02
Oslo, Norway 11 April 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular mRNA technology for next generation nucleic
acid medicine, today announces that its subsidiary Circio AB has entered a
research evaluation agreement with Lonza, one of the world's largest contract
development and manufacturing organizations.
The research license enables Circio to test the circVec circular mRNA expression
technology in Lonza's proprietary transient expression system for protein
production. Further updates will follow as necessary as the project progresses.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Neil Hunter - Hunter PR
Phone:+44 7821 255568 (http://tel:+447821255568)
Email: neiljameshunter@gmail.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.